CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.35B, above the global median of $1.18B
- FinancialsAltman Z-Score 2.17: grey zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.22%
Annual Rate
CNY 0.35Paid annual
Payout Ratio
46.7%Sustainable
Payback Period
85.0 yr
Last Ex-Dividend
Jun 12, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
9.02BCNY1.35B · vs all stocks (USD)
Trailing P/E
38.13xvs Biotechnology peers
Revenue (TTM)
2.03BCNY303.64M · vs all stocks (USD)
Profit Margin
11.67%vs Biotechnology peers
Beta
0.2630xvs all stocks
52-Week Change
-30.95%vs all stocks
Market Capitalization
9.02BCNY1.35B · vs all stocks (USD)
Enterprise Value
11.10BCNY1.66B · vs all stocks (USD)
Trailing P/E
38.13xvs Biotechnology peers
Forward P/E
13.88xvs Biotechnology peers
Price to Sales (TTM)
4.44xvs Biotechnology peers
Price to Book (MRQ)
2.92xvs Biotechnology peers
Enterprise to Revenue
5.46xvs Biotechnology peers
Enterprise to EBITDA
13.85xvs Biotechnology peers
Gross Margin
57.17%vs Biotechnology peers
Profit Margin
11.67%vs Biotechnology peers
Operating Margin
25.01%vs Biotechnology peers
Return on Assets (TTM)
4.28%vs Biotechnology peers
Return on Equity (TTM)
7.66%vs Biotechnology peers
Revenue (TTM)
2.03BCNY303.64M · vs all stocks (USD)
Revenue per Share (TTM)
6.46CNYUpdated Sep 22, 2026Quarterly Revenue Growth
21.50%vs Biotechnology peers
Gross Profit (TTM)
1.07BCNY159.36M · vs all stocks (USD)
EBITDA (TTM)
831.59MCNY124.13M · vs all stocks (USD)
Net Income (TTM)
237.42MCNY35.44M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-45.60%vs Biotechnology peers
Operating Cash Flow (TTM)
675.32MCNY100.80M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-607.00MCNY-90.61M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.3500CNYUpdated Sep 22, 2026Trailing Annual Dividend Yield
1.22%vs all stocks
Payout Ratio
46.67%vs Biotechnology peers
Minority Interest (Equity)
16.20MCNYFY2025 · Dec 31, 2025Revenue
1.94BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
725.75MCNYFY2025 · Dec 31, 2025Gross Profit
1.22BCNYFY2025 · Dec 31, 2025Operating Income
552.13MCNY82.42M · vs all stocks (USD)
Pre-tax Income
360.49MCNYFY2025 · Dec 31, 2025Income Tax Expense
35.08MCNYFY2025 · Dec 31, 2025Net Income
325.41MCNYFY2025 · Dec 31, 2025EBIT
425.95MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
831.59MCNYFY2025 · Dec 31, 2025Research & Development
251.92MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
164.58MCNYFY2025 · Dec 31, 2025Other Operating Expenses
25.45MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
10.16MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
65.46MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.06CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.06CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
313.60MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
313.60MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
325.41MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
7.01MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
27.67MCNYFY2025 · Dec 31, 2025Free Cash Flow
-1.34BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
802.01MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
325.41MCNYFY2025 · Dec 31, 2025Other Non-cash Items
75.83MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
68.38MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-441.94MCNYFY2025 · Dec 31, 2025Capital Expenditures
-1.37BCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.07BCNYFY2025 · Dec 31, 2025Sale of Investments
1.14BCNYFY2025 · Dec 31, 2025Other Investing Activity
-282.53KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.30BCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
2.50BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.35BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-239.60MCNYFY2025 · Dec 31, 2025Other Financing Charges
15.99MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
926.37MCNYFY2025 · Dec 31, 2025Shares Outstanding
316.05MSharesUpdated Sep 22, 2026Float Shares
182.42MSharesUpdated Sep 22, 2026% Held by Insiders
44.28%vs all stocks
% Held by Institutions
0.45%vs all stocks
Total Cash (MRQ)
956.79MCNY142.82M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.03CNYUpdated Sep 22, 2026Total Debt (MRQ)
2.83BCNY422.72M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.9130xvs Biotechnology peers
Current Ratio (MRQ)
1.14xvs Biotechnology peers
Book Value per Share (MRQ)
9.78CNYUpdated Sep 22, 2026Total Assets
6.74BCNY1.01B · vs all stocks (USD)
Total Current Assets
2.51BCNYFY2025 · Dec 31, 2025Total Liabilities
3.74BCNYFY2025 · Dec 31, 2025Total Non-current Assets
4.23BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
1.58BCNYFY2025 · Dec 31, 2025Total Current Liabilities
2.16BCNYFY2025 · Dec 31, 2025Cash
802.01MCNYFY2025 · Dec 31, 2025Cash Equivalents
111.78MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
913.79MCNYFY2025 · Dec 31, 2025Other Short-term Investments
116.00MCNYFY2025 · Dec 31, 2025Accounts Receivable
500.68MCNYFY2025 · Dec 31, 2025Inventory
859.52MCNYFY2025 · Dec 31, 2025Accounts Payable
667.84MCNYFY2025 · Dec 31, 2025Short-term Debt
1.31BCNYFY2025 · Dec 31, 2025Other Current Liabilities
3.57MCNYFY2025 · Dec 31, 2025Long-term Debt
1.35BCNYFY2025 · Dec 31, 2025Common Stock (Book)
316.05MCNYFY2025 · Dec 31, 2025Retained Earnings
809.45MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.00BCNY448.07M · vs all stocks (USD)
52-Week Low
25.70CNYUpdated Sep 22, 202652-Week High
41.90CNYUpdated Sep 22, 202652-Week Change
-30.95%vs all stocks
Beta
0.2630xvs all stocks
50-Day MA
27.87CNYUpdated Sep 22, 2026200-Day MA
31.25CNYUpdated Sep 22, 2026Avg 10-Day Volume
1.88MSharesUpdated Sep 22, 2026Avg 30-Day Volume
2.44MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
0.7500CNYUpdated Sep 22, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Is this company growing?
Multi-Year Revenue And Profit Growth
Revenue and earnings have both grown steadily across six years.
Reads
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 2.17: grey zoneSignificant
Altman Z-Score: 2.17
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.35B, above the global median of $1.18BNotable
Market cap (USD): 1,346,433,482.568Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Alpha Tau Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule
EL.En. S.p.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chengdu Easton Bio Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
GenFleet Therapeutics (Shanghai) Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Beijing Hotgen Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Garden Bio-chemical High-tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Conmed Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Vcanbio Cell & Gene Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Oric Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Grupo Mateus S.A.
3 interpretationsOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthMulti-Year Revenue And Profit Growth
Beijing Caishikou Department Store Co., Ltd.
3 interpretationsOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthMulti-Year Revenue And Profit Growth
Suzhou Shihua New Material Technology Inc.
3 interpretationsOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthMulti-Year Revenue And Profit Growth